Impact of HPV vaccination on HPV infection and cervical related disease burden in real-world settings (HPV-RWS): protocol of a prospective cohort

Zhike Liu, Pei Li, Xueyang Zeng, Xiaoying Yao, Yexiang Sun, Hongbo Lin, Peng Shen, Feng Sun, Siyan Zhan, Zhike Liu, Pei Li, Xueyang Zeng, Xiaoying Yao, Yexiang Sun, Hongbo Lin, Peng Shen, Feng Sun, Siyan Zhan

Abstract

Background: Cervical cancer is one of the most common cancers in women and could be prevented by human papilloma virus (HPV) vaccination. Cervarix, the first available HPV vaccine, has been widely administrated to Chinese women, while little was known about its effect on the prevention and control for HPV related diseases in China. The study aims to assess the impact of Cervarix on HPV infection and cervical related diseases in real world.

Methods: This is a prospective, multi-age birth cohort study to investigate the incidence and continuous status of HPV infection, and relevant cervical diseases by exposure status (with Cervarix vaccination history or without any HPV vaccination history). It is planned to recruit 12,118 eligible women at age of 9 to 45 years from vaccination clinics or hospital outpatient clinics, and then follow up them for three years. The standard questionnaire will be used to collect information such as demographic characteristics, menstruation and obstetrical histories, history of sexual behavior, personal behavior history, history of disease and pathogen infection, medication history, and family history at baseline. After three years, the changes of these behaviors will be investigated again, and other related health status information will be retrieved from the electronic health records during the follow-up period. If available physically and legally, the cervical cancer screening will be performed, including type-specific HPV deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) testing and contingent thinprep cytologic test (TCT) and colposcopy. The free cervical cancer screening will be captured and uploaded timely to the Yinzhou Regional Health Information Platform (YRHIP); therefore, the long-term outcomes of participants will be monitored.

Discussion: This prospective cohort study will assess the impact of HPV vaccine on HPV infection and related cervical diseases in women aged 9-45 years, which makes up for the lack of evidence in Chinese women. The results of this study will provide support for understanding the impact of HPV vaccination in China, and make a contribution to increasing HPV vaccination and cervical cancer screening coverage in China.

Trial registration: This study has been retrospectively registered on clinicaltrials.gov (NCT05341284) on April 22, 2022.

Keywords: Cervical cancer; Cervical cancer screening; HPV vaccine; Prospective cohort.

Conflict of interest statement

FS and PS, as the primary investigators from Peking University and Yinzhou CDC, will receive funding from GlaxoSmithKline Biologicals SA (GSK), which is the manufacturer of cervarix and will potentially benefit from the result of this study.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Cervical cancer screening procedure
Fig. 2
Fig. 2
Study procedure

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660.
    1. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191–e203. doi: 10.1016/S2214-109X(19)30482-6.
    1. Zhang S, Sun K, Zheng R, Zeng H, Wang S, Chen R, et al. Cancer incidence and mortality in China, 2015. J Nat Cancer Cent. 2021;1(1):2–11. doi: 10.1016/j.jncc.2020.12.001.
    1. Li X, Zheng R, Li X, Shan H, Wu Q, Wang Y, et al. Trends of incidence rate and age at diagnosis for cervical cancer in China, from 2000 to 2014. Chin J Cancer Res. 2017;29(6):477–486. doi: 10.21147/j.issn.1000-9604.2017.06.02.
    1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–19. doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>;2-F.
    1. Chen W, Zhang X, Molijn A, Jenkins D, Shi JF, Quint W, et al. Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18. Cancer Causes Control. 2009;20(9):1705–1713. doi: 10.1007/s10552-009-9422-z.
    1. WHO . Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: World Health Organization; 2020.
    1. Liu YJ, Zhang Q, Hu SY, Zhao FH. Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China. BMC Cancer. 2016;16:164. doi: 10.1186/s12885-016-2207-3.
    1. National Medical Products Administration . The nonavalent HPV vaccine is licensed with conditional approval. 2018.
    1. National Medical Products Administration . The First Domestic HPV Recombinant HPV Vaccine is Licensed. 2019.
    1. National Medical Products Administration . The General Administration approved the marketing of human papillomavirus adsorbed vaccine. 2016.
    1. Women's Health Care Branch of Chinese Preventive Medical Associatio . Comprehensive preventino and control guidelines for cervical cancer in China. Beijing: People's Medicl Publishing House; 2017.
    1. He Q. The first HPV vaccination programme in China: the Jungar Banner in Erdos. Beijing: Health Times; 2020.
    1. Shen H. The HPV vaccine would be free fo school girls in Xiamen. 2020.
    1. Maternal and Child Health Department MoH. Circular of the Ministry of Health and the All-China Women's Federation on printing and distributing the management plan of the "Two Cancer Screening Projects" for rural women. Bulletin of the Ministry of Health, PRC. 2009(08):44-54.
    1. Hoes J, Pasmans H, Knol MJ, Donken R, van Marm-Wattimena N, Schepp RM, et al. Persisting Antibody response 9 years after bivalent Human Papillomavirus (HPV) vaccination in a cohort of Dutch women: immune response and the relation to genital HPV infections. J Infect Dis. 2020;221(11):1884–1894. doi: 10.1093/infdis/jiaa007.
    1. Paraskevaidis E, Athanasiou A, Paraskevaidi M, Bilirakis E, Galazios G, Kontomanolis E, et al. Cervical pathology following HPV vaccination in Greece: a 10-year HeCPA observational cohort study. In Vivo. 2020;34(3):1445–1449. doi: 10.21873/invivo.11927.
    1. Herweijer E, Feldman AL, Ploner A, Arnheim-Dahlström L, Uhnoo I, Netterlid E, et al. The participation of HPV-vaccinated women in a National Cervical Screening Program: Population-Based Cohort Study. PLoS ONE. 2015;10(7):e0134185. doi: 10.1371/journal.pone.0134185.
    1. Thamsborg LH, Napolitano G, Larsen LG, Lynge E. Impact of HPV vaccination on outcome of cervical cytology screening in Denmark-A register-based cohort study. Int J Cancer. 2018;143(7):1662–1670. doi: 10.1002/ijc.31568.
    1. Song Y, Liu X, Yin Z, Yu W, Cao L, Cao K, et al. Human papillomavirus vaccine coverage among 9–45-year-old female population of China in 2018–2020. Chin J Vaccines Immun. 2021;27(05):570–575.
    1. Zhao FH, Lewkowitz AK, Hu SY, Chen F, Li LY, Zhang QM, et al. Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies. Int J Cancer. 2012;131(12):2929–2938. doi: 10.1002/ijc.27571.
    1. Lin H, Tang X, Shen P, Zhang D, Wu J, Zhang J, et al. Using big data to improve cardiovascular care and outcomes in China: a protocol for the CHinese Electronic health Records Research in Yinzhou (CHERRY) Study. BMJ Open. 2018;8(2):e019698. doi: 10.1136/bmjopen-2017-019698.
    1. Drolet M, Bénard É, Pérez N, Brisson M. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394(10197):497–509. doi: 10.1016/S0140-6736(19)30298-3.
    1. Johnson Jones ML, Gargano JW, Powell M, Park IU, Niccolai LM, Bennett NM, et al. Effectiveness of 1, 2, and 3 doses of human papillomavirus vaccine against high-grade cervical lesions positive for human papillomavirus 16 or 18. Am J Epidemiol. 2020;189(4):265–276. doi: 10.1093/aje/kwz253.
    1. Lei J, Ploner A, Elfström KM, Wang J, Roth A, Fang F, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383(14):1340–1348. doi: 10.1056/NEJMoa1917338.
    1. Oliveira CR, Niccolai LM. Monitoring HPV vaccine impact on cervical disease: Status and future directions for the era of cervical cancer elimination. Prev Med. 2021;144:106363. doi: 10.1016/j.ypmed.2020.106363.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren